There is a light at the end of the tunnel in terms of hotspots, but the impact on the developed world’s economies is still unclear.
RBC presents multiple downturn scenarios exist that vary by depth and duration.
Expect a surge in elective surgeries once the focus of healthcare turns from the COVID-19 surge to business as usual.
Expect more market volatility—both to the downside and upside.
Medtech start-ups should prepare now for the ‘business as usual’ that is coming with fresh investor decks and strategies for fund-raising.
Plan to run your medtech organization ‘lean and mean’ until we are completely in the clear.
CONTACT US
LOOKING FOR A ‘LEAN AND MEAN’ MEDTECH PARTNER WITH KEY INSIGHTS INTO MEDICAL DEVICE STRATEGY AND TRENDS?
OUR LAST THREE PROJECTS WERE:
Medtech product strategy development: legacy product in a commodity space with potential for a meaningful digital health component
Medtech digital health price sensitivity conjoint study
M&A third party analysis of a medtech company with a digital health medical element (done in two weeks)